Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ingevity Corporation filings document formal disclosure for its specialty materials business, public-company governance, and capital structure. Form 8-K reports cover operating results, segment reporting presentation, credit agreement amendments, material agreements, and completed dispositions of North Charleston crude tall oil refinery assets and the majority of the Industrial Specialties product line.
Proxy and annual-meeting filings disclose director elections, board structure, executive compensation matters, shareholder voting results, and amendments to the company’s equity incentive plan. The filing record also includes disclosures tied to financing arrangements, continuing-operations measures, and governance matters affecting Ingevity’s common stock as a NYSE-listed issuer.
Ingevity Corp senior vice president and chief HR officer Terrance M. Dyer reported equity compensation and a related tax withholding transaction. He received a grant of 3,621 shares of common stock at $0.00 per share, tied to restricted stock units that vest in three equal installments on February 27, 2027, 2028, and 2029. To cover tax withholding on 2025 RSUs that vested, 550 shares were disposed at $71.64 per share. After these transactions, he directly holds 7,698 common shares.
Ingevity Corp senior executive receives equity award. SVP and President, APT, Michael N. Shukov acquired 1,389 shares of Ingevity common stock on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan.
The units will vest in three equal installments on February 27, 2027, February 27, 2028, and February 27, 2029, aligning the executive’s compensation with longer-term company performance through time-based vesting.
Castillo Ruth reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp senior executive Ruth Castillo, SVP and President of Performance Materials, reported receiving a grant of 3,688 shares of common stock as a stock award. These restricted stock units were granted at no cash cost and will vest in three equal installments on February 27, 2027, 2028, and 2029.
Li David H reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp President & CEO David H. Li reported an equity award of 38,179 shares of common stock. The filing labels this as a grant or award, with a price of $0.0000 per share, indicating it is a stock-based compensation grant rather than an open-market purchase.
According to the footnotes, the award consists of restricted stock units granted under the Ingevity Corporation 2025 Omnibus Incentive Plan and scheduled to vest in three equal installments on February 27, 2027, 2028, and 2029. After this grant, Li’s directly held common stock position is reported as 156,890 shares, which includes earlier purchases of 364 and 162 shares through the company’s employee stock purchase plan.
Ingevity Corp EVP and CFO Mary Dean Hall reported equity award activity involving company common stock. On February 26, 2026, she acquired 1,780 shares through the settlement of performance-based restricted stock units after the Talent and Compensation Committee certified that performance goals were met. On the same date, 873 shares were withheld by the company to cover tax obligations related to these vested awards. Following these transactions, she directly owned 41,775 shares of Ingevity common stock.
Ingevity Corp senior executive Richard Allen White Jr., SVP and President of Performance Chemicals, reported stock-based compensation awards of common stock. On February 26, 2026, he acquired 1,204 shares at $0 per share and 430 shares at $70.52 per share as grant or award transactions. Footnotes explain that performance-based restricted stock units were certified and settled in common shares rather than cash.
Ingevity Corp senior vice president Phillip John Platt reported equity compensation activity involving company common stock. On February 26, 2026, he acquired 247 shares at no cost through a grant tied to performance-based restricted stock units that were settled in shares. On the same date, 108 shares at $70.52 per share were withheld by the company to cover tax obligations related to these vested performance share units. Following these transactions, his directly held common stock balance reported in the filing was 28,911 shares.
Ingevity Corp senior vice president and general counsel Ryan C. Fisher reported equity compensation activity involving company common stock. On February 26, 2026, he acquired 192 shares at a stated price of $0.00 per share from the vesting and settlement of performance-based restricted stock units. On the same date, the company withheld 94 shares at a price of $70.52 per share to cover tax obligations related to this vesting. After these transactions, Fisher directly owned 15,393 shares of Ingevity common stock.
Ingevity Corp senior vice president Clarence Reid Clontz Jr. reported performance-based equity compensation activity involving company common stock. On February 26, 2026, he acquired 187 shares of common stock at $0.00 per share as a grant related to performance-based restricted stock awards (PSUs) whose performance goals were certified and settled in stock.
On the same date, 69 shares were disposed of at $70.52 per share through shares withheld by the company to cover tax withholding obligations tied to the PSU vesting, rather than an open-market sale. After these transactions, he directly held 7,363 common shares, which includes 216 shares previously purchased through the company’s employee stock purchase plan.
Ingevity Corporation is reshaping its portfolio around a streamlined “New Ingevity” model after a comprehensive strategic review. It sold its North Charleston crude tall oil refinery and most of the Performance Chemicals industrial specialties product line on January 1, 2026, which are reported as discontinued operations.
New Ingevity will center on two higher‑margin businesses, Performance Materials and Pavement Technologies, while the company explores strategic alternatives for the Advanced Polymer Technologies segment and the road markings product line, targeted for completion by the end of 2026. In 2025, segment revenue was $606.9 million for Performance Materials, $400.5 million for Performance Chemicals, and $160.2 million for Advanced Polymer Technologies. Ingevity also faces an approximately $85.0 million antitrust judgment in the BASF dispute, with $95.4 million accrued including post‑judgment interest and payment expected in the second quarter of 2026, while reporting a 29% reduction in personal and process safety incidents versus 2024.